1. Home
  2. MGRX vs MRKR Comparison

MGRX vs MRKR Comparison

Compare MGRX & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mangoceuticals Inc.

MGRX

Mangoceuticals Inc.

HOLD

Current Price

$0.87

Market Cap

15.6M

Sector

Technology

ML Signal

HOLD

Logo Marker Therapeutics Inc.

MRKR

Marker Therapeutics Inc.

HOLD

Current Price

$1.85

Market Cap

16.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MGRX
MRKR
Founded
2021
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.6M
16.6M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
MGRX
MRKR
Price
$0.87
$1.85
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$10.17
AVG Volume (30 Days)
1.1M
301.1K
Earning Date
11-14-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$466,908.00
$4,694,988.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.52
$0.81
52 Week High
$6.15
$4.07

Technical Indicators

Market Signals
Indicator
MGRX
MRKR
Relative Strength Index (RSI) 43.45 75.06
Support Level $0.65 $1.45
Resistance Level $0.90 $1.55
Average True Range (ATR) 0.15 0.12
MACD 0.02 0.04
Stochastic Oscillator 39.83 87.31

Price Performance

Historical Comparison
MGRX
MRKR

About MGRX Mangoceuticals Inc.

Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.

Share on Social Networks: